Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track NGEN with free AI briefings, catalyst countdowns, and dilution alerts.

NGEN · NervGen Pharma Corp.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$86.8M Cash on Hand

40.6mo Cash Runway

Follow NGEN by email Get an email when NGEN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NGEN, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Jul 2027 · Phase 3 · Recruiting · A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal C
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
NVG-291	Chronic Spinal Cord Injury	Phase 3 · NCT07799532	Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NGEN holds $86.8M in cash and short-term investments and burns about $6.4M/quarter from operations, an estimated runway of 40.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Cash runway 41 months

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NGEN files for a raise →

Get the full NGEN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NGEN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z